Australian Government: Australian Institute of Health and Welfare METeOR Home Page

Cervical cancer staging (FIGO) code N[N]

Identifying and definitional attributes

Metadata item type:Help on this termValue Domain
Synonymous names:Help on this termFIGO cervical cancer stage code
METeOR identifier:Help on this term424187
Registration status:Help on this termHealth, Standard 08/05/2014
Definition:Help on this termA code set representing the International Federation of Gynecology and Obstetrics (FIGO) cancer stage values for cervical cancer.

Representational attributes

Representation class:Help on this termCode
Data type:Help on this termNumber
Format:Help on this termN[N]
Maximum character length:Help on this term2
Permissible values:Help on this term
ValueMeaning
1Stage IA1
2Stage IA2
3Stage IB1
4Stage IB2
5Stage IIA1
6Stage IIA2
7Stage IIB
8Stage IIIA
9Stage IIIB
10Stage IVA
11Stage IVB
Supplementary values:Help on this term
99Not available/inadequately described

Collection and usage attributes

Guide for use:Help on this term

International Federation of Gynecology and Obstetrics (FIGO) stage according to 2009 definitions. Data on patients affected by Stage 0 disease is not collected.

Stage I: the carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded).

Stage IA: invasive carcinoma that can be diagnosed only by microscopy, with deepest invasion less than or equal to 5 mm and largest extension less than or equal to 7 mm.

CODE 1   Stage IA1

Measured stromal invasion of less than or equal to 3.0 mm in depth and extension of less than or equal to 7.0 mm.

CODE 2   Stage IA2

Measured stromal invasion of greater than 3.0 mm and less than 5.0 mm with an extension of not more than 7.0 mm.

Stage IB: clinically visible lesions limited to the cervix uteri or preclinical cancers greater than stage IA.

CODE 3   Stage IB1

Clinically visible lesion less than or equal to 4.0 cm in greatest dimension.

CODE 4   Stage IB2

Clinically visible lesion greater than 4.0 cm in greatest dimension.

Stage II: cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina.

Stage IIA: without parametrial invasion.

CODE 5   Stage IIA1

Clinically visible lesion less than or equal to 4.0 cm in greatest dimension.

CODE 6   Stage IIA2

Clinically visible lesion greater than 4.0 cm in greatest dimension.

CODE 7   Stage IIB

With obvious parametrial invasion.

Stage III: the tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney.

CODE 8   Stage IIIA

Tumour involves lower third of the vagina, with no extension to the pelvic wall.

CODE 9   Stage IIIB

Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney.

Stage IV: the carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV.

CODE 10   Stage IVA

Spread of the growth to adjacent organs.

CODE 11   Stage IVB

Spread to distant organs.

Source and reference attributes

Submitting organisation:Help on this termCancer Australia
Reference documents:Help on this termMutch, D G (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology. 115: 325–328

Relational attributes

Data elements implementing this value domain:Help on this term

Person with cancer—extent of primary cancer, cervical cancer staging (FIGO) code N[N] Health, Standard 08/05/2014

Classification scheme attributes

Classification scheme:International Federation of Gynecology and Obstetrics cancer staging system
Synonymous names:Help on this termFIGO cancer staging system
METeOR identifier:Help on this term531364
Registration status:Help on this termHealth, Standard 08/05/2014
Definition:Help on this term

The International Federation of Gynecology and Obstetrics cancer staging system is an international system for coding gynaecological cancer, including cervical, endometrial, ovarian and vulval cancer. This system was developed by International Federation of Gynecology and Obstetrics (FIGO) in 1958, and most recently updated in 2009.

The two purposes of this system are to allow for comparison of patient treatment and outcomes across both treatment centres and population groups, and to divide patients into prognostic groups.

Source and reference attributes

Submitting organisation:Help on this termCancer Australia
Reference documents:Help on this term

Mutch, D G 2009. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology 115:325–328. Viewed 12 July 2013,

http://xa.yimg.com/kq/groups/20406181/1805956361/name/
The+new+FIGO+staging+system.pdf

My items Help on this term
Download Help on this term